"I am profoundly grateful to Mrs. Mazumdar-Shaw for her generosity and vision in establishing the Mazumdar-Shaw Translational Research Initiative for kidney cancer at Memorial Sloan Kettering Cancer Center (MSK). Your gift has significantly boosted our research programs and will help us expand our decades-long work of leading global clinical studies...
Biocon Biologics Acquires Viatris’ Global Biosimilars Business
Biocon Biologics a subsidiary of Biocon Ltd., based in Bangalore, India, successfully completed its multi-billion dollar acquisition of the global biosimilars business of its partner Viatris Inc. headquartered in Canonsburg, Pennsylvania. Viatris received a $2 billion upfront cash payment and $1 billion in Compulsorily Convertible Preference Shares, representing a stake...
16th Biopharma Summit Recognizes India’s InnovationPotential
The USA-India Chamber of Commerce (USAIC) held its 16th annual BioPharma & Healthcare Summit virtually on June 24. The event was well attended by industry leaders, academicians, and investors, as well as government officials from both countries. Attendees included Lawrence Tabak, acting director, National Institutes of Health, and Max Bronstein,...
India's Kiran Mazumdar-Shaw Elected to MIT Board
Kiran Mazumdar-Shaw, chairperson and managing director of Bangalore, India-based Biocon, was elected as a full-term member of the MIT Corporation, the Board of Trustees of the Massachusetts Institute of Technology. She is among the eight full-term members who will each serve a term of five years starting July 1, 2018....
Biocon India Receives US FDA Approval for Biosimilar
India's Bangalore-based Biocon Ltd is the country's first company to have a "biosimilar" approved in the U.S. for Roche’s drug Trastuzumab, marketed as Herceptin, and used in treating certain breast and stomach cancers. Kiran Mazumdar-Shaw, the company’s chairperson and managing director said, "This was the first biosimilar for Herceptin approved...
Biocon receives authorization to sell Psoriasis drug in India
Biocon (a Biotechnology Company with headquarters in Bangalore, India) has received the marketing authorization from the Drugs Controller general of India for Novel Biologic Itolizumab (used for the treatment of chronic plaque Psoriasis). Itolizumab has an excellent safety profile as indicated during the 52-week clinical study conducted in India. This...